The FDA has issued a warning about Strattera (atomoxetine), a drug used to treat attention deficit hyperactivity disorder (ADHD) in adults and children.

They have required that the labeling be updated to include a bolded warning about the potential for severe liver damage. Two patients using Strattera for several months, have suffered severe liver damage, but fortunately have recovered.

The new labeling warns that severe liver injury may progress to liver failure and death. It also warns that the medication should be discontinued in patients who develope jaundice.

Strattera has been in use since 2002. Clinical trials comprising 6,000 people turned up no ill side effects.

Signs of liver failure include: itchy skin, jaundice, dark colored urine, upper right side abdominal tenderness and unexplained "flue-like" symptoms.

Register your Strattera Case

If you feel you qualify for damages or remedies that might be awarded in a possible Strattera class action or lawsuit, please fill in our form on the right to submit your complaint.

Reader Comments

Posted by

I recently had an exam done by my physician and he saw that m6 liver was enlarged. I've been taking stratter for over a year now and i have never had liver issues

Add Your Comment on This Issue

Fields marked * are mandatory. Please read our comment guidelines before posting.


Note: Your name will be published with your comment.

*Email Address:

Your email will only be used if a response is needed.

*Your Comment:
Request Legal Help